摘要
目的探讨吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用。方法回顾性分析中国医学科学院肿瘤医院100例非小细胞肺癌术后行吉西他滨联合顺铂方案辅助治疗患者的临床资料。结果 100例患者共完成372个化疗周期,中位化疗周期数为4个周期,4个周期化疗完成率为85%,其中76例(76%)完成了计划的全剂量化疗。吉西他滨的中位剂量为8 377.1 mg/m2,中位剂量强度708 mg.m-2.周-1;顺铂的中位剂量为293.38 mg/m2,中位剂量强度25.24 mg.m-2.周-1。Ⅲ度以上血液学毒性包括粒细胞减少(27.5%)、血小板计数减少(9.9%)、白细胞计数减少(9.0%)和贫血(1.1%)。随访2.40～46.72个月,死亡5例,均为ⅢA期患者。随访超过1年的患者有74例,1年无复发生存率为78.4%;随访2年以上的有21例,2年无复发生存率为85.7%。结论吉西他滨联合顺铂辅助治疗非小细胞肺癌,毒性较小,耐受性好,1年及2年的疾病控制率高,但是否能够降低术后患者的复发率,提高远期生存,尚需5年随访的证据支持。
Objective To evaluate efficacy and toxicity of gemcitabine combined with cisplatin as adjuvant chemother- apy in non - small cell lung cancer. Methods Clinical data of 100 NSCLC patients admitted to our hospital who received adjuvant chemotherapy of gemcitabine combined with cisplatin were retrospectively analyzed. Results 372 chemotherapy cycles were com- pleted among 100 patients, and the median chemotherapy cycle was 4. The completion rate of 4 cycles was 85%, with 76 cases （76%） completing full dose chemotherapy. The median dose and median dose intensity of gemcitabine were 8 377. 1 mg/m^2 and 708 mg · m^-2 ·w^-1 respectively; the median dose and median dose intensity of cisplatin were 293.38 mg/m^2 and 25.24 mg·m^-2 · w^-1 respectively. Hematological toxicities over grade Ⅲ were granulocytopenia （27.5%） , thrombocytopenia （9. 9% ） , neutropenia （9.0%） and anemia （ 1.1% ） . During the 2.40 to 46. 72 months following up, 5 patients died, all being m A stage cases. 74 cases were followed up more than one year, and one year recurrence - free survival rate was 78.4% ; 21 eases were followed up more two years, and two year recurrence - free survival rate was 85.7%. Conclusion The combination of cispl- atin and gemcitabine is of low toxicity and well - tolerated in the adjuvant treatment with high disease control rate in one or two years. However, we need further data of 5 year survival and recurrence free survival rate to support the efficacy.
出处
《中国全科医学》
CAS
CSCD
北大核心
2012年第9期987-989,共3页
Chinese General Practice
关键词
癌
非小细胞肺癌
吉西他滨
顺铂
抗肿瘤联合化疗方案
Carcinoma, non - small - cell lung
Gemcitabine
Cisplatin
Antineoplastic combined chemotherapyprotocds
